First Line KEYTRUDA® Superior to Chemotherapy in Metastatic MSI-H/dMMR Colorectal Cancer
Salvage YERVOY® and OPDIVO® Combination after Prior Immune Checkpoint Inhibitor Therapy in Advanced RCC
High Tumor Mutational Burden Predicts Response to KEYTRUDA®
FDA Approves KEYTRUDA® Plus Chemotherapy for Triple Negative Breast Cancer
Chemotherapy-Free First Line Induction and Consolidation Treatment for Acute Lymphocytic Leukemia
FDA Approves OPDIVO® plus YERVOY® for Malignant Pleural Mesothelioma
Immune Checkpoint Inhibitors Associated with High Activity in MSI-H Cancers
Optimal Duration of Immune Checkpoint Inhibitors in Advanced Non Small Cell Lung Cancer
OPDIVO® plus CABOMETYX® Combination Doubles Progression Free Survival in Newly Diagnosed Advanced Kidney Cancer
FDA Approves IO in Combination with Targeted Therapies for BRAF Positive Advanced Melanoma
FDA Approves KEYTRUDA® for Tumor Mutational Burden-High Solid Tumors
Overall Survival Benefit with Frontline OPDIVO® plus YERVOY® and Limited Chemotherapy in NSCLC
Late Breaking Abstract – ASCO 2020: FDA Approves BAVENCIO® for Maintenance Treatment in Advanced Urothelial Carcinoma
KEYTRUDA® Superior to ADCETRIS® in Relapsed or Refractory Classical Hodgkin Lymphoma
Late Breaking Abstract – ASCO 2020: First Line KEYTRUDA® Superior to Chemotherapy in Metastatic MSI-H/dMMR Colorectal Cancer
FDA Approves Chemotherapy-Free First Line Immunotherapy Combination in Advanced NSCLC
FDA Approves KEYTRUDA® for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer
FDA Approves IMFINZI® for Advanced Small Cell Lung Cancer
Lung Immune Prognostic Index (LIPI) is an Important Prognostic Biomarker for Patients with Advanced Non Small Cell Lung Cancer
FDA Approves Frontline TECENTRIQ® with Carboplatin and nab-Paclitaxel for Metastatic Non-Squamous NSCLC
Bottom Ad
Advertisement
Subscribe
